Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16790678 | 0.81 | ALDH1A1 (0.38) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL16790676 | 0.81 | MAPT (0.35) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL16801806 | 0.78 | ALDH1A1 (0.40) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL14279868 | 0.78 | PRMT6 (0.36) | ALDH1A1HPGD | |
| SCHEMBL6343950 | 0.75 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL16790677 | 0.73 | TAAR1 (0.47) | MEN1ALDH1A1MAPTKMT2A | |
| SCHEMBL6348740 | 0.72 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL12845997 | 0.71 | ALDH1A1 (0.36) | ALDH1A1 | |
| SCHEMBL16790697 | 0.71 | HPGD (0.40) | MEN1ALDH1A1MAPTHPGDKMT2A | |
| SCHEMBL6346574 | 0.70 | ALDH1A1 (0.35) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077385-B1 | HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | CHIESI FARM SPA (IT) | 2017-10-04 | — | — | EP | disclosed |
| US-9133185-B2 | Heteroaryl derivatives | CHIESI FARMACEUTICI S.P.A (IT) | 2015-09-15 | — | — | US | disclosed |
| US-20150158858-A1 | HETEROARYL DERIVATIVES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-11 | — | — | US | disclosed |
| WO-2015082616-A1 | HETEROARYL DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | CHIESI FARMACEUTICI S.P.A. (IT) | 2015-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150158858-A1 | HETEROARYL DERIVATIVES | PDE4A, PDE4B, PDE3A | MEN1 4265/4885ALDH1A1 608/4885GLA 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.